Join the Fidabio Mobilization
CSL Behring, Bern, adopted a Fida 1 to perform accurate protein binding and concentration analysis directly in plasma and serum.
Fachhochschule, Basel, implemented a Fida 1 instrument amongst others to carry out complex oligomeric analysis and develop comprehensive assays for determining molecular integrity.
The Jørgen Kjems Group at the Interdisciplinary Nanoscience Center at Aarhus University has after intensive testing implemented their first Fida 1 instrument primarily for protein-nucleotide interactions analysis.
Fachhochschule, Basel, got their second Fida 1 instrument.
DTU Bioengineering, Andreas H. Laustsen, has acquired a Fidabio system for high-throughput biophysical characterization of therapeutic antibodies etc.
Agilent has acquired a Fida 1 amongst others to enable them to ensure consistent, high quality of their antibodies through the determination of quantity and affinity with a single FIDA analysis.
Exosome therapeutics leader, Codiak Biosciences, Inc., has acquired a Fida 1 to quantify and characterise exosomes directly in the fermentation media.
A completely new way to quantify and characterize complex biology
Essential New insight
Quantitative data on complex protein binding, concentration, size etc.
At Fidabio, we are committed to assist you in accelerating your R&D projects. For this we have developed the FIDA technology enabling simple, accurate, and fast detection and characterization of proteins & nanoparticles under native conditions.